Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Reporting at EULAR, researchers found that opioid use by patients with rheumatic and musculoskeletal pain was on the rise in Europe.

Whether it be fentanyl, tramadol or tilidine, new European figures show that increasingly more people are taking opioids for pain connected with rheumatic and musculoskeletal diseases.

The European League Against Rheumatism (EULAR) reported the findings at its recent virtual conference and warned of a growing risk of opioid abuse in Europe, calling for measures to use these analgesics more safely.

NDORMS DPhil Junqing Xie was lead author of a study that analysed the use opioids in patients with osteoarthritis in Catalonia, Spain from 2007 – 2016. Reviewing the health data of approximately six million patients, his research showed the use of the medication increased from 15 to 25 percent during that time.

"Taking opioids, in particular strong opioids, has substantially increased in recent years in patients newly suffering from osteoarthritis," said Junqing. "Precautions must urgently be taken so that these medications are prescribed safely."

The Catalonia study identified certain groups that showed an increased risk for addiction or dependency. Women were 4% more often affected than men, the elderly were 10% more affected than younger populations, and those with a lower socioeconomic status were 6% more likely to be affected than more privileged groups. Residents of rural areas were 1% more likely to take opioids compared to urban residents.

A separate study in Iceland not only showed that the taking of opioids frequently continues even after the source of pain has gone, but that their consumption actually increases. "It is a matter of urgency", says EULAR President Professor Iain B. McInnes from Glasgow, Scotland, UK.

Opioids are strong analgesics effective for patients with chronic non-tumor associated pains, such as chronic osteoarthritis. However, after a prescribed dose of treatment they should stop being taken. Their strong side effects include effects to the central nervous system which are sometimes mood enhancing. "This accounts for their strong addiction potential: For most patients, the physical withdrawal is therefore the most difficult," said Professor Ulf Müller-Ladner, EULAR Past Chair of Standing Committee on Clinical Affairs and Medical Director of the Rheumatology and Clinical Immunology Department of the Kerckhoff Clinic in Bad Nauheim, Germany.

The risk of physical and psychological addiction development is, however, low when opioids are used as intended. "Therefore, we would like to raise awareness of a responsible approach both by the prescribers and also the patients", says Professor John Isaacs from the University of Newcastle, UK, who is currently the EULAR Scientific Committee Chair.

Similar stories

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Unlocking the secrets of the microbiome

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.

Into the future: watching biology unfold

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.

New Botnar Research Institute Director starts today

Professor Jonathan Rees begins his new role as Director of the Botnar Research Institute today, taking over from Professor Andrew Carr.

Patient and public involvement in Rheumatology research – embracing the wave of change

On launching the new OPEN ARMS PPI group in Oxford, Dr. Laura Coates explored the patient and public involvement (PPI) models of three academic centres in the UK to show how it benefits researchers, clinicians, and patients alike.